Markets around the world, including the US and China, all took a big drop during the uncertainty surrounding President ...

Gilead Sciences' TROP2-directed drug Trodelvy has missed the target in another clinical trial, this time in urothelial carcinoma, the most common form of bladder cancer. The results of the TROPiCS ...

On the same day as it reported encouraging new data for its cancer drug Trodelvy, Gilead Sciences has agreed a deal to buy rights to the drug in Asia held by Chinese drugmaker Everest Medicines ...

Gilead Sciences shows strong Q1 execution, pipeline momentum, and margin upside, led by HIV and PrEP launches. See why GILD stock is a strong buy.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue expectations and prompted a negative market reaction. Management attributed ...

In Trodelvy’s home base of second-line TNBC, the Gilead drug is the only one that has demonstrated an overall survival benefit.

By Deena Beasley (Reuters) -Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when ...

Gilead Sciences (NASDAQ:GILD) announced Saturday that its antibody-drug conjugate Trodelvy, in combination with Merck’s (NYSE:MRK) immunotherapy Keytruda, cut the risk of disease progression or ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses primary results from ASCENT-04 ...

Gilead Sciences (NasdaqGS:GILD) recently achieved FDA approval for Yeztugo, a significant step in HIV prevention as the first ...

Results from the Phase III ASCENT-04/KEYNOTE-D19 trial demonstrated that Merck’s Keytruda combined with Gilead’s Trodelvy reduced the risk of disease progression or death by 35% in patients with PD-L1 ...